Avant Technologies and global biotechnology firm, Austrianova, have announced the official launch of their joint venture, Klothonova LLC and its groundbreaking Klotho development programme.
This initiative aims to engineer a genetically modified cell line that overexpresses the Klotho protein, paving the way for innovative cell-based therapies to combat age-related diseases such as Alzheimer's and cancer, while also advancing anti-ageing and longevity treatments.
By harnessing Austrianova's proprietary cell-encapsulation technology, Klothonova is positioning itself at the forefront of anti-ageing biotechnology.
The programme's initial phase has focused on R&D based proof of concept studies.
A population of genetically modified human cells has been generated by Austrianova and shown to over-produce the Klotho protein.
These cells were then successfully encapsulated in Austrianova's proprietary Cell-in-Box technology and shown to produce similar amounts of the Klotho protein to that produced by non-encapsulated cells.
Although non-optimised, the encapsulated cells used in the study demonstrate quite clearly the feasibility of using encapsulated cells to continuously produce the Klotho protein.
The next stage for the programme is to move forward with a proprietary GMP-grade human cell clone that will be used in preclinical and eventually clinical studies.
In preparation for this next stage, Austrianova is conducting routine servicing and requalification on its already ISO9001:2015 compliant, state-of-the-art GMP isolator and facility and preparing the necessary documentation needed for the next steps of the programme.
These essential steps will ensure the reproducibility and safety of the Klotho protein-producing cell lines, laying a strong foundation for producing high-quality clinical-grade therapeutics.
"The R&D level proof of concept study provides a clear rationale for the programme, giving a green light to move to GMP studies."
"In addition, the meticulous preparations of the GMP facility at Austrianova represent a foundational milestone in bringing Klotho-based therapies to patients who need them most," said Chris Winter, CEO of Avant Technologies.
"By prioritising GMP compliance from the outset, Klothonova is committed to delivering safe, effective treatments that could transform the landscape of age-related disease management."
Dr Brian Salmons, CEO of Austrianova, added, "Once again our encapsulation technology has proven it is ideal for long-term continuous production of yet another protein, in this case, Klotho."
"Our expertise in cell encapsulation, combined with Avant's innovative vision, makes this joint venture uniquely positioned for success."
"The preparations we are undertaking today ensure that every cell we produce meets the highest standards of quality and safety, accelerating our path toward clinical trials."
This development programme builds on the joint venture agreement signed in September 2025, which established Klothonova as a Nevada-based entity equally owned by Avant and Austrianova's affiliate, SGAustria Pte. Ltd.
The JV's focus on Klotho — a protein renowned for its anti-ageing and protective effects on organs — aligns with growing market demand for cell-based therapies, projected to reach $44bn globally.